Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2

Oncogene

Volumn 26, Issue 34, 2007, Pages 4897-4907

  Winter, S F ^a   Acevedo, V D ^b   Gangula, R D ^b   Freeman, K W ^b,c   Spencer, D M ^b   Greenberg, N M ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Angiopoietin; FGFR1; Prostate; Transgenic

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PD 173074; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; IN VIVO STUDY; MALE; MOLECULAR DYNAMICS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR VASCULARIZATION;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; CELL LINE; EPITHELIUM; MALE; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTATE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS);

MUS MUSCULUS;

EID: 34547401519     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210288     Document Type: Article

References (40)

1. American Cancer Society (2006). Cancer Facts and Figures 2006. American Cancer Society: Atlanta, GA.
2. Bergers G, Benjamin LE. (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
3. Bicknell R, Harris AL. (2004). Novel angiogenic signaling pathways and vascular targets. Annu Rev Pharmacol Toxicol 44: 219-238.
4. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. (1997). Biological roles of fibroblast growth factor-2. Endocr Rev 18: 26-45.
5. Dery MA, Michaud MD, Richard DE. (2005). Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37: 535-540.
6. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. (2001). Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 49: 293-305.
7. Dorkin TJ, Robinson MC, Marsh C, Neal DE, Leung HY. (1999). aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol 189: 564-569.
8. Foley KP, Leonard MW, Engel JD. (1993). Quantitation of RNA using the polymerase chain reaction. Trends Genet 9: 380-385.
9. Folkman J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
10. Folkman J, Hanahan D. (1991). Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 22: 339-347.
11. Folkman J, Shing Y. (1992). Angiogenesis. J Biol Chem 267: 10931-10934.
12. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613.
13. Foster BA, Kaplan PJ, Greenberg NM. (1999). Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostatic Dis 2: 76-82.
14. Freeman KW, Welm BE, Gangula RD, Rosen JM, Ittmann M, Greenberg NM et al. (2003). Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res 63: 8256-8263.
15. Giri D, Ropiquet F, Ittmann M. (1999). Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063-1071.
16. Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC, Leung HY. (2003). FGF8 isoform b expression in human prostate cancer. Br J Cancer 88: 1432-1438.
17. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO et al. (1995). Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439-3443.
18. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M et al. (1994). The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 8: 230-239.
19. Hayward SW, Baskin LS, Haughney PC, Cunha AR, Foster BA, Dahiya R et al. (1996). Epithelial development in the rat ventral prostate, anterior prostate and seminal vesicle. Acta Anat (Basel) 155: 81-93.
20. Hobbs S, Jitrapakdee S, Wallace JC. (1998). Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 252: 368-372.
21. Huss WJ, Barrios RJ, Foster BA, Greenberg NM. (2003). Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 54: 8-16.
22. Javerzat S, Auguste P, Bikfalvi A. (2002). The role of fibroblast growth factors in vascular development. Trends Mol Med 8: 483-489.
23. Jin C, Wang F, Wu X, Yu C, Luo Y, McKeehan WL. (2004). Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors. Cancer Res 64: 4555-4562.
24. Kim I, Kim JH, Ryu YS, Jung SH, Nah JJ, Koh GY. (2000). Characterization and expression of a novel alternatively spliced human angiopoietin-2. J Biol Chem 275: 18550-18556.
25. Kwabi-Addo B, Ozen M, Ittmann M. (2004). The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11: 709-724.
26. Lind AJ, Wikstrom P, Granfors T, Egevad L, Stattin P, Bergh A. (2005). Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 62: 394-399.
27. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
28. Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH et al. (1998). Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 17: 5896-5904.
29. Nakamura T, Mochizuki Y, Kanetake H, Kanda S. (2001). Signals via FGF receptor 2 regulate migration of endothelial cells. Biochem Biophys Res Commun 289: 801-806.
30. Tait CR, Jones PF. (2004). Angiopoietins in tumours: the angiogenic switch. J Pathol 204: 1-10.
31. Thomson AA. (2001). Role of androgens and fibroblast growth factors in prostatic development. Reproduction 121: 187-195.
32. Wang F, McKeehan K, Yu C, Ittmann M, McKeehan WL. (2004). Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia. Prostate 58: 1-12.
33. Wang GL, Semenza GL. (1995). Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270: 1230-1237.
34. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. (2006). Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 103: 1480-1485.
35. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409.
36. Weidner N, Semple JP, Welch WR, Folkman J. (1991). Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
37. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM. (2002). Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol 157: 703-714.
38. Winter SF, Cooper AB, Greenberg NM. (2003). Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis 6: 204-211.
39. Zhang J, Thomas TZ, Kasper S, Matusik RJ. (2000). A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141: 4698-4710.
40. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G et al. (2003). Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63: 3403-3412.